US IPO market closes April with four pricings led by three biotech listings as SPAC activity returns to the market
Four IPOs (initial public offerings — first-time share sales on a public exchange) priced in the final week of April, capping a month characterised by activity at the biotech end of the market. The week was led by three sizable biotech listings, with coagulation disorder specialist Hemab Therapeutics (ticker: COAG) upsizing its offering and pricing at the top of its range to raise $302 million — a strong signal of institutional demand for specialist life-sciences paper. The week also saw eleven blank-check listings, a reference to SPACs (special purpose acquisition companies — shell companies that raise capital in an IPO to later merge with a private target), marking a notable uptick in that corner of the market. Investor Bill Ackman featured among the final-week closings, adding a high-profile name to what would otherwise have been a technically driven week. The data covers US exchange activity, though the performance of biotech IPOs at the top of their ranges carries read-across for London-listed life-sciences issuers and cross-border ECM (equity capital markets) mandates handled by City firms with dual-listed clients.
Why this matters
Biotech IPOs pricing at the top of their ranges indicate genuine institutional appetite even in an uncertain macro environment — this matters to ECM practices advising life-sciences companies considering public listings on either side of the Atlantic. The return of SPAC activity, even at modest volumes, is worth monitoring: SPAC structures require legal work on prospectus drafting, trust account mechanics, and eventual de-SPAC merger documentation. The Hemab upsizing suggests the biotech window remains open for well-positioned issuers, which could accelerate UK and European life-sciences companies that have been holding IPO plans in reserve.
On the Ground
A trainee on a biotech IPO would be proofreading prospectus sections for accuracy against the company's clinical trial data, coordinating verification notes with the issuer's scientific advisers, and preparing PDMR (person discharging managerial responsibilities) notification letters for directors selling into the offer.
Interview prep
Soundbite
Biotech IPOs pricing above range signal an open window that cross-listed UK life-sciences issuers should move quickly to exploit.
Question you might get
“What are the key differences between a traditional IPO bookbuild and a SPAC de-SPAC merger process from a legal documentation perspective?”
Full answer
The final week of April saw four US IPOs price, including Hemab Therapeutics raising $302 million at the top of its range, alongside eleven SPAC listings — together signalling that the IPO market is functioning for the right assets. This matters for City ECM lawyers because a functioning US biotech window typically encourages UK and European life-sciences companies to accelerate their own listing timelines, generating mandates for prospectus, listing, and underwriting work. The broader trend is one of selective market reopening: investors are backing high-quality, niche biotech paper while remaining cautious on generalist sectors. This suggests law firms advising on dual-track processes — private placement versus IPO — will see clients increasingly favour public routes for biotech assets.
My notes
saved